Early Phase Clinical Trials: Canada

Submit A Letter of Intent

Sign in to our online system or register for a new account to submit a letter of intent.

Apply Now

Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments.

The Early Phase Clinical Trials: Canada program was created to provide funding support for clinical trials and clinical trial sub-studies that have excellent preliminary data.

NEW for 2018:

  1. The Institute has updated which tools are in scope. Please read the What We Fund page before applying to ensure your project is in scope.
  2. The Early Phase Clinical Trials: Canada program will now be run on a rolling basis. Applicants may submit an LOI at any time and will be notified of whether to prepare a full Proposal within ~2 months of LOI submission.

Program Overview

Please refer to the Program Details  and Request for Applications (RFA)  document for more information.

Goal: To provide funding to support clinical trials and/or clinical trial sub-studies that could accelerate the development of therapeutics for neurodegenerative disease aging.

Funding: A maximum of $1,500,000 per project over up to 4 years

Applicant Eligibility:

Eligible Principal Applicants must be at or above the level of Assistant Professor or equivalent, and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. Co-applicants and Collaborators must be at the post-doctoral level or above, and can be working outside Canada.

Applicants may appear in any role on any number of projects.

Project Eligibility: 

Projects must meet these conditions to be eligible:

  • Be a clinical trial(s) and/or a clinical trial sub-study(s) that accelerates the development of therapeutics for neurodegenerative diseases of aging.
    • Projects that require only up to $200,000 over up to 18 months may also be submitted to the Rapid Response program.
    • Translational research other than clinical trials and/or clinical trial sub-studies should be submitted to the Transformational Research program or the Rapid Response program.
  • Be the development of a therapeutic and/or tool.

Please refer to the What We Fund page for Institute definitions of neurodegenerative diseases of aging, translational research, therapeutic, tool, and clinical trials.

The Institute encourages applicants to contact us (neuro@weston.ca or +1 416-935-4056) with any questions regarding this program, including whether a potential idea is in scope.

Application Process

There are two stages to the application process:

  1. Letters of Intent (LOI)
  2. Proposal

An application requires the submission of a Letter of Intent which will be reviewed by our scientific review committee. Applicants with high potential projects will then be invited to submit a Proposal. Instructions for submitting the Proposal will be forwarded to those invited.

Applicants can expect to receive the outcome of their LOI application within ~2 months of submission.

Program Details

Request for Applications (RFA)

Letter of Intent sample


The Institute welcomes inquiries about this program or any of our other funding opportunities. Contact us at neuro@weston.ca or +1 416-935-4056.


Back to Programs